Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2012 - New Study Released

Oct. 19, 2012 - PRLog -- Global Markets Direct's, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2012', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/463858_chronic_kidney_disease_...
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure).
* A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Chronic Kidney Disease (Chronic Renal Failure) therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Products under Development, Key Players in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics, Chronic Kidney Disease (Chronic Renal Failure) Pipeline Overview, Chronic Kidney Disease (Chronic Renal Failure) Pipeline, Chronic Kidney Disease (Chronic Renal Failure) Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure)
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Products under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
Abbott Laboratories
Amgen Inc.
Eli Lilly and Company
Isis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Merck & Co., Inc.
FibroGen, Inc.
MD Scientific, LLC
Astellas Pharma Inc.
Kureha Corporation
Cyclacel Pharmaceuticals Inc.
Nile Therapeutics, Inc.
Alexion Pharmaceuticals, Inc.
Panacea Biotec Limited
Pieris AG
Hawthorn Pharmaceuticals, Inc.
Promedior, Inc.
Reata Pharmaceuticals, Inc.
Angion Biomedica Corp.
Thrasos, Inc.
Concert Pharmaceuticals, Inc.
CorMedix, Inc.
Vitae Pharmaceuticals, Inc.
Stelic Institute & Co.
Zenyaku Kogyo Co., Ltd.
Ardelyx, Inc.
Sorbent Therapeutics, Inc.
InVasc Therapeutics, Inc.
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
YM533 - Drug Profile
LY2127399 - Drug Profile
FG-3019 - Drug Profile
Sensipar - Drug Profile
Bardoxolone Methyl - Drug Profile
Bardoxolone Methyl - Drug Profile
PRS-080 - Drug Profile
Soliris - Drug Profile
CU-NP - Drug Profile
Seliciclib - Drug Profile
Kremezin - Drug Profile
THR-123 - Drug Profile

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4638...

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.